NASDAQ:CLVS - Clovis Oncology Stock Price, Forecast & News

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.89) by $0.17. The biopharmaceutical company earned $37.60 million during the quarter, compared to analysts' expectations of $35.84 million. Clovis Oncology had a negative net margin of 298.53% and a negative return on equity of 1,576.32%. Clovis Oncology's revenue was up 65.2% compared to the same quarter last year. During the same period last year, the business earned ($1.71) earnings per share. View Clovis Oncology's Earnings History.

Clovis Oncology is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Clovis Oncology.

Clovis Oncology will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Clovis Oncology issued an update on its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $38.3-39.3 million, compared to the consensus revenue estimate of $40.39 million.

15 Wall Street analysts have issued 12-month price objectives for Clovis Oncology's shares. Their forecasts range from $4.00 to $36.00. On average, they expect Clovis Oncology's stock price to reach $19.91 in the next year. This suggests a possible upside of 114.3% from the stock's current price. View Analyst Price Targets for Clovis Oncology.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 1 sell rating, 7 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Clovis Oncology.

Media headlines about CLVS stock have trended somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Clovis Oncology earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Clovis Oncology.

Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), Intercept Pharmaceuticals (ICPT), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Alibaba Group (BABA), Incyte (INCY), Exelixis (EXEL), Amarin (AMRN) and NVIDIA (NVDA).

Clovis Oncology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.09%), Alpine Global Management LLC (0.07%), Janney Montgomery Scott LLC (0.04%) and McAdam LLC (0.03%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.

CLVS stock was sold by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe and Paul Edward Gross. View Insider Buying and Selling for Clovis Oncology.

CLVS stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Alpine Global Management LLC and McAdam LLC. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLVS stock can currently be purchased for approximately $9.29.

Clovis Oncology has a market capitalization of $509.18 million and generates $95.39 million in revenue each year. The biopharmaceutical company earns $-368,010,000.00 in net income (profit) each year or ($7.07) on an earnings per share basis. View Additional Information About Clovis Oncology.

The official website for Clovis Oncology is http://www.clovisoncology.com/.

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]